Malignant pleural mesothelioma (PM) is a highly aggressive disease of the lung pleura associated with poor prognosis. Despite advances in improving the clinical management of this malignancy, there is no effective chemotherapy for refractory or relapsing PM. The acquisition of resistance to standard and targeted therapy in this disease is a foremost concern; therefore, a deeper understanding of the complex factors surrounding the emergence of drug resistance is deemed necessary. In this review, we will present broad insights into various cellular and molecular concepts, accounting for the recalcitrance of PM to chemotherapy, including signaling networks regulating drug tolerance, drug resistance-associated proteins, genes, and miRNAs, as well as the critical role of cancer stem cells. Identification of the biological determinants and their associated mechanisms may provide a framework for the development of appropriate treatment.
恶性胸膜间皮瘤是一种高度侵袭性的胸膜疾病，预后极差。尽管该恶性肿瘤的临床管理已取得进展，但对于难治性或复发性胸膜间皮瘤仍缺乏有效的化疗方案。该疾病对标准化治疗及靶向治疗产生耐药性已成为首要关注问题，因此有必要深入理解药物耐药性产生的复杂因素。本综述将从多角度探讨胸膜间膜瘤化疗耐受性的细胞与分子机制，包括调控药物耐受的信号网络、耐药相关蛋白、基因及miRNA的作用，以及肿瘤干细胞的关键影响。明确这些生物学决定因素及其作用机制，可为制定针对性治疗方案提供理论框架。
肿瘤(癌症)患者之家